Compare · AZN vs EWTX
AZN vs EWTX
Side-by-side comparison of AstraZeneca PLC (AZN) and Edgewise Therapeutics Inc. (EWTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and EWTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $248.18B, about 52.1x EWTX ($4.76B).
- AZN has been more active in the news (27 items in the past 4 weeks vs 7 for EWTX).
- AZN has more recent analyst coverage (25 ratings vs 16 for EWTX).
- Company
- AstraZeneca PLC
- Edgewise Therapeutics Inc.
- Price
- -
- -
- Market cap
- $248.18B
- $4.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 27
- 7
- Recent ratings
- 25
- 16
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
- Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
- SEC Form 6-K filed by AstraZeneca PLC
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest EWTX
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- Amendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael
- Amendment: SEC Form 4 filed by CMO Donovan Joanne M.
- Amendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J
- Amendment: SEC Form 4 filed by General Counsel Moore John R
- Amendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad
- SEC Form 4 filed by Chief Financial Officer Nofi Michael
- General Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)
- CMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)